BIA responds to House of Commons Health and Social Care Committee report on antimicrobial resistance

The BioIndustry Association (BIA) has responded to the House of Commons Health and Social Care Committee report on antimicrobial resistance released today.

BIA CEO, Steve Bates, said:  “Today’s Commons Committee report is right to highlight the need for continued political focus on AMR. The BIA’s report and video highlights the great work being done on AMR by smaller UK companies.  A key point that Lord Jim O’Neill’s evidence overlooks is that, on current trends, more AMR innovation looks set to come from this community than from established pharma.”

The BIA explainer document and video feature case studies from Destiny Pharma, Matoke, Neem Biotech, Novabiotics and Summit Therapeutics. For more information and to download these materials go to the BIA website.  

Editors Notes

Explainer report: Antimicrobial Resistance

Video: Antimicrobial Resistance

Contact: Ed Sexton, Senior Communications Manager, BIA 

[email protected] 02076302196

About the BIA                    

Established over 25 years ago at the infancy of biotechnology, the BioIndustry Association (BIA) is the trade association for innovative enterprises involved in UK bioscience. Members include emerging and more established bioscience companies; pharmaceutical companies; academic, research and philanthropic organisations; and service providers to the bioscience sector. The BIA represents the interests of its members to a broad section of stakeholders, from government and regulators to patient groups and the media. Our goal is to secure the UK's position as a global hub and as the best location for innovative research and commercialisation, enabling our world-leading research base to deliver healthcare solutions that can truly make a difference to people's lives.   

For further information, please go to www.bioindustry.org and twitter.com/BIA_UK